-
Telmisartan in Cardiac Hypertrophy Research
2026-09-21
Telmisartan provides an upstream AT1-receptor control for separating angiotensin II-driven hypertrophy from downstream RIP3/CaMKII mechanisms. This article presents practical dosing, signaling, imaging, and troubleshooting workflows for cardiovascular disease research.
-
Gastrodin, AT1 Signaling, and Reactive Astrocytes
2026-09-20
The reference study used a microglia-conditioned medium model to show that gastrodin reshapes renin–angiotensin system, SIRT3, inflammatory, and neurotrophic responses in reactive astrocytes. Pharmacological inhibition with Azilsartan supported an AT1-linked contribution to astrocyte phenotype changes, while the cellular design also highlights important limits for translating these findings beyond in vitro neuroinflammation models.
-
Fosinopril sodium: Applied ACE Inhibitor Workflows
2026-09-19
Fosinopril sodium supports mechanistic ACE inhibition studies, hypertension research, and translational cardiovascular disease models with a distinctive phosphinic acid scaffold and prodrug pharmacology. This guide pairs assay-ready preparation steps with renal hemodynamics workflows and practical troubleshooting for reproducible results.
-
Anlotinib Hydrochloride: Assay Logic
2026-09-19
Anlotinib hydrochloride is a multi-target tyrosine kinase inhibitor whose anti-angiogenic phenotype is best understood through linked target-engagement, endothelial, and translational assays. This guide converts preclinical evidence into a decision framework for rigorous cancer research without confusing pathway inhibition with nonspecific cytotoxicity.
-
AZD0156: ATM Kinase Inhibitor Workflow Guide
2026-09-18
Build more informative DNA damage response experiments with AZD0156 by combining ATM target engagement, double-strand break assays, and functional combination testing. This workflow distinguishes direct pathway inhibition from nonspecific cytotoxicity and supports biomarker-led cancer therapy research.
-
COX-2 Controls Muscle Ischemia After Venom Injury
2026-09-17
A Microvascular Research study identifies a time-dependent role for cyclooxygenase-2 in Bothrops asper venom-induced muscle injury. Lumiracoxib-associated early pathway inhibition worsened acute ischemia but was linked to stronger later VEGF, CD31, and MMP responses, clarifying how COX-2 can be vascularly protective at one stage and restraining of revascularization at another.
-
Hyperthermia–Cisplatin Activates Caspase-8
2026-09-17
The reference study identifies caspase-8 accumulation and activation as a mechanistic link between hyperthermia and cisplatin-enhanced apoptosis and pyroptosis. Its combination of ubiquitination analysis, genetic perturbation, biochemical assays, and ultrastructural imaging provides a framework for interpreting caspase-8-dependent cell death rather than treating caspase activation as a single endpoint.
-
Telmisartan for Reliable Cardiac Assays
2026-09-17
This scenario-driven guide explains how Telmisartan (SKU A8531) can strengthen angiotensin II cardiac hypertrophy, viability, and cytotoxicity workflows. It covers DMSO formulation, assay controls, dose planning, orthogonal readouts, and practical vendor-selection criteria for cardiovascular disease research.
-
Targeted SPP1 Inhibition Reprograms TAMs
2026-09-16
The reference study introduces a phenotypic screening strategy to identify small molecules that reduce SPP1 expression in tumor-associated macrophages, then incorporates promising hits into a TAM-avid polymeric nanoconstruct. Its lead formulation, CANDI460, lowered SPP1 in vitro and in vivo and produced tumor remissions across murine models, providing a framework for macrophage-directed cancer immunotherapy.
-
Angiotensin II: From GPCR Signal to Vascular Insight
2026-09-15
A translational framework for using Angiotensin II to connect GPCR signaling with endothelial dysfunction, vascular remodeling, hypertension mechanisms, and abdominal aortic aneurysm models.
-
Azilsartan: A Causal RAS Assay Framework
2026-09-15
Azilsartan (TAK-536) enables receptor-level interrogation of angiotensin II signaling in cardiovascular and neuroinflammation models. This article translates a reactive astrocyte–microglia study into a rigorous assay framework focused on causal interpretation, controls, and reproducibility.
-
Losartan Workflows for AT1R and Kidney Research
2026-09-14
Losartan is a practical angiotensin II receptor antagonist for separating AT1R-dependent signaling from upstream trafficking defects in podocytes, vascular cells, and hypertension models. This guide combines assay-ready preparation, mechanistic readouts, and troubleshooting strategies for reproducible cardiovascular and diabetic kidney research.
-
VX-745: A Practical p38α MAPK Inhibitor Workflow
2026-09-14
VX-745 combines strong biochemical potency for p38α with a practical workflow for cytokine, proliferation, aging, and arthritis studies. This guide translates pathway biology and recent kinase-conformation research into assay setup, protocol choices, and troubleshooting steps.
-
ICAA Targets RIP3 in Cardiac Hypertrophy
2026-09-13
A 2026 Cellular Signalling study identifies isochlorogenic acid A (ICAA) as a protective compound that directly targets RIP3 and suppresses downstream CaMKII signaling in angiotensin II- and pressure overload-induced cardiac hypertrophy. The work separates RIP3-dependent hypertrophic remodeling from canonical MLKL signaling and provides a mechanistic framework for cardiovascular disease research.
-
ICAA Targets RIP3 in Ang II Cardiac Hypertrophy
2026-09-12
The reference study identifies isochlorogenic acid A (ICAA) as a protective compound that acts on RIP3 and suppresses downstream CaMKII signaling during angiotensin II- and pressure overload-induced cardiac hypertrophy. Its key mechanistic contribution is showing that RIP3 regulates hypertrophic remodeling independently of MLKL, providing a rationale for studying the RIP3/CaMKII axis as a distinct therapeutic pathway.